Cannabinoids

InMed Pharmaceuticals Inc (TSX:IN; OTCQX:IMLFF) Chief Business Officer Josh Blacher speaks with Proactive Investor’s Christine Corrado about how the biopharma company is changing the game in the cannabinoid space. Blacher says the Vancouver based company, which specializes in developing therapeutics to treat a variety of diseases, is disrupting the space with its cannabinoid biosynthesis technology, […]

by

VANCOUVER, British Columbia, Oct. 04, 2018 (GLOBE NEWSWIRE) — Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE: ATT) (OTC: ATTBF) is pleased to announce that the research being done in conjunction with the University of British Columbia and Mitacs is close to completing their phase of testing. In Q1 2018, Abattis announced a research study […]

by

1. During one month at a single medical center in Illinois in 2018, 34 cases of synthetic cannabinoid associated coagulopathy were identified. 2. Of the 15 patients who underwent anticoagulant poisoning testing, all 15 were positive for brodifacoum. Evidence Rating Level: 4 (Below Average)         Study Rundown: Synthetic cannabinoids are produced to mimic the user experience of […]

by

Save Article Naturally Splendid Enterprises Ltd. (TSXV:NSP), a biotech stock, moved higher after announcing that CROP Infrastructure will now utilize NSP’s HempOmega powder in its “CannaDrink” Sean Mason | October 3, 2018 | SmallCapPower Development of a cannabinoid beverage was good news for investors in a biotech stock Wednesday. Here’s some small stocks making big moves on Wednesday, […]

by

TSX: INOTCQX:IMLFF VANCOUVER, Oct. 3, 2018 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX:IMLFF), a cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, is pleased to announce entering into a research agreement with the National Research Council of […]

by

Highlights• AusCann releases online education courses as part of its Medical Outreach Program to support Australian health professionals make informed decisions regarding cannabinoid therapeutics.  Tuesday, 2 October 2018 – Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (AusCann or ‘the Company’) is pleased to advise it has today released a series of online courses for Australian health […]

by

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to […]

by

Rhinomed has signed a 12-year exclusive licensing agreement with Columbia Care LLC, the largest and most experienced manufacturer and provider of medical cannabis products and services in the United States. Technology company Rhinomed (ASX: RNO) has made an assertive move into the drug delivery market by signing a…read more at https://smallcaps.com.au/rhinomed-licensing-deal-columbia-care-cannabinoid-delivery/

by

Synthetic cannabinoid research from local university gets national recognition Copyright 2018 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Video …read more at https://www.centralillinoisproud.com/news/local-news/synthetic-cannabinoid-research-from-local-university-gets-national-recognition/1479917689

by

“But that’s a pretty vast operation,” he said. “And as the DEA, we certainly have an interest in tracking drug samples in our region: through drug purchases, seizures, intelligence from people who cooperate with us, and from people in the medical community. And, very sadly, we track drug trends through toxicology reports” — on victims of fatal […]

by

Project CBD, a California-based educational non-profit, has published an in-depth Primer on Cannabinoid-Drug Interactions for health professionals, patients, and public policy-makers. The 33-page report, summarized below, is available for free download at the bottom of the page. Drug interactions are a significant consideration in modern medicine. More than half of U.S. adults regularly take prescription meds […]

by

Treatment with EHP-102, an investigational cannabinoid-derived medicine, reduced weight loss, preserved motor neurons of the spinal cord, and lowered the abnormal reactivity of astroglial cells in a mouse model of amyotrophic lateral sclerosis (ALS), new research shows. Findings were recently published in the study, “Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an […]

by

The extraction of cannabinoids from cannabis plants is a huge and growing industry. From edibles to portable vape cartridges, cannabinoid extraction makes all kinds of products possible. There are several different methods of extracting cannabinoids from the plant. But all of them are resource-intensive processes requiring large quantities of raw cannabis. But what if it […]

by